Gÿorgý Kéri

8.0k total citations
162 papers, 6.1k citations indexed

About

Gÿorgý Kéri is a scholar working on Molecular Biology, Oncology and Epidemiology. According to data from OpenAlex, Gÿorgý Kéri has authored 162 papers receiving a total of 6.1k indexed citations (citations by other indexed papers that have themselves been cited), including 86 papers in Molecular Biology, 45 papers in Oncology and 26 papers in Epidemiology. Recurrent topics in Gÿorgý Kéri's work include Neuroendocrine Tumor Research Advances (23 papers), HER2/EGFR in Cancer Research (15 papers) and Lung Cancer Treatments and Mutations (15 papers). Gÿorgý Kéri is often cited by papers focused on Neuroendocrine Tumor Research Advances (23 papers), HER2/EGFR in Cancer Research (15 papers) and Lung Cancer Treatments and Mutations (15 papers). Gÿorgý Kéri collaborates with scholars based in Hungary, Germany and United States. Gÿorgý Kéri's co-authors include László Őrfi, Henrik Daub, Zoltán Greff, Jesper V. Olsen, András Váradi, Balázs Sarkadi, Felix Oppermann, Matthias Mann, Florian Gnad and Axel Ullrich and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Molecular Cell.

In The Last Decade

Gÿorgý Kéri

162 papers receiving 6.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Gÿorgý Kéri Hungary 41 3.5k 1.7k 592 540 535 162 6.1k
Ching‐Shih Chen United States 44 4.7k 1.4× 1.0k 0.6× 915 1.5× 521 1.0× 682 1.3× 144 6.8k
Pramod S. Pandey United States 43 5.3k 1.5× 1.2k 0.7× 673 1.1× 346 0.6× 617 1.2× 95 7.2k
Stig Linder Sweden 49 4.8k 1.4× 2.0k 1.2× 335 0.6× 1.0k 1.9× 981 1.8× 151 7.1k
Ross L. Stein United States 41 5.8k 1.7× 2.1k 1.2× 795 1.3× 774 1.4× 818 1.5× 131 8.1k
Alex N. Bullock United Kingdom 49 6.1k 1.7× 2.8k 1.6× 872 1.5× 259 0.5× 1.1k 2.0× 108 8.7k
Ji Cao China 43 3.2k 0.9× 1.2k 0.7× 314 0.5× 501 0.9× 1.2k 2.2× 142 5.4k
John F. Timms United Kingdom 40 4.2k 1.2× 1.2k 0.7× 182 0.3× 376 0.7× 787 1.5× 103 6.7k
Juan Carlos Lacal Spain 54 5.7k 1.6× 1.8k 1.1× 290 0.5× 333 0.6× 1.8k 3.4× 162 8.4k
Mikihiko Naito Japan 54 6.6k 1.9× 3.5k 2.0× 445 0.8× 565 1.0× 609 1.1× 224 9.7k
Klaus P. Hoeflich United States 36 4.8k 1.4× 2.0k 1.2× 290 0.5× 443 0.8× 776 1.5× 62 6.8k

Countries citing papers authored by Gÿorgý Kéri

Since Specialization
Citations

This map shows the geographic impact of Gÿorgý Kéri's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gÿorgý Kéri with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gÿorgý Kéri more than expected).

Fields of papers citing papers by Gÿorgý Kéri

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gÿorgý Kéri. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gÿorgý Kéri. The network helps show where Gÿorgý Kéri may publish in the future.

Co-authorship network of co-authors of Gÿorgý Kéri

This figure shows the co-authorship network connecting the top 25 collaborators of Gÿorgý Kéri. A scholar is included among the top collaborators of Gÿorgý Kéri based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gÿorgý Kéri. Gÿorgý Kéri is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bánhegyi, Gábor, et al.. (2017). Molecular subtype specific efficacy of MEK inhibitors in pancreatic cancers. PLoS ONE. 12(9). e0185687–e0185687. 22 indexed citations
2.
Micsík, Tamás, András Lörincz, Zsolt Baranyai, et al.. (2015). Decreased functional activity of multidrug resistance protein in primary colorectal cancer. Diagnostic Pathology. 10(1). 26–26. 10 indexed citations
3.
Garamvölgyi, Rita, Judit Dobos, Eszter Illyés, et al.. (2015). Design and synthesis of new imidazo[1,2- a ]pyridine and imidazo[1,2- a ]pyrazine derivatives with antiproliferative activity against melanoma cells. European Journal of Medicinal Chemistry. 108. 623–643. 31 indexed citations
4.
5.
Szokol, Bálint, Ferenc Baska, Csaba Szántai-Kis, et al.. (2014). Discovery and Biological Evaluation of Novel Dual EGFR/c-Met Inhibitors. ACS Medicinal Chemistry Letters. 5(4). 298–303. 12 indexed citations
6.
Haas, Darya A., Kiran Bala, Guntram Büsche, et al.. (2013). The Inflammatory Kinase MAP4K4 Promotes Reactivation of Kaposi's Sarcoma Herpesvirus and Enhances the Invasiveness of Infected Endothelial Cells. PLoS Pathogens. 9(11). e1003737–e1003737. 29 indexed citations
7.
Sharma, Kirti, Christoph K. Weber, Michaela Bairlein, et al.. (2009). Proteomics strategy for quantitative protein interaction profiling in cell extracts. Nature Methods. 6(10). 741–744. 104 indexed citations
8.
Cheburkin, Yu. V., Kirti Sharma, László Őrfi, et al.. (2008). AXL Is a Potential Target for Therapeutic Intervention in Breast Cancer Progression. Cancer Research. 68(6). 1905–1915. 170 indexed citations
9.
10.
Schwab, Richárd, Tamás Micsík, Eszter Schäfer, et al.. (2007). Functional Evaluation of Multidrug Resistance Transporter Activity in Surgical Samples of Solid Tumors. Assay and Drug Development Technologies. 5(4). 541–550. 5 indexed citations
11.
Horváth, Anikó, János Seprődi, Tibor Vántus, et al.. (2007). Effect of New Synthetic Peptides and Peptidomimetics on Angiogenesis. 2006. 249–250. 1 indexed citations
12.
Gonzalo, Teresa, Leonie Beljaars, M. van de Bovenkamp, et al.. (2007). Local Inhibition of Liver Fibrosis by Specific Delivery of a Platelet-Derived Growth Factor Kinase Inhibitor to Hepatic Stellate Cells. Journal of Pharmacology and Experimental Therapeutics. 321(3). 856–865. 61 indexed citations
13.
Temming, Kai, M. Lacombe, Roel Q.J. Schaapveld, et al.. (2006). Rational Design of RGD–Albumin Conjugates for Targeted Delivery of the VEGF‐R Kinase Inhibitor PTK787 to Angiogenic Endothelium. ChemMedChem. 1(11). 1200–1203. 29 indexed citations
14.
Prakash, Jai, Maria Sandovici, Vinay Saluja, et al.. (2006). Intracellular Delivery of the p38 Mitogen-Activated Protein Kinase Inhibitor SB202190 [4-(4-Fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)1 H-imidazole] in Renal Tubular Cells: A Novel Strategy to Treat Renal Fibrosis. Journal of Pharmacology and Experimental Therapeutics. 319(1). 8–19. 53 indexed citations
15.
Godl, Klaus, Oliver J. Gruß, Jan Eickhoff, et al.. (2005). Proteomic Characterization of the Angiogenesis Inhibitor SU6668 Reveals Multiple Impacts on Cellular Kinase Signaling. Cancer Research. 65(15). 6919–6926. 84 indexed citations
16.
Brehmer, Dirk, Zoltán Greff, Klaus Godl, et al.. (2005). Cellular Targets of Gefitinib. Cancer Research. 65(2). 379–382. 199 indexed citations
17.
Schwab, Richárd, István Peták, Edit Szabó, et al.. (2005). [Epidermal growth factor receptor (EGFR): therapeutic target in the treatment of lung adenocarcinoma].. PubMed. 146(46). 2335–42. 2 indexed citations
18.
Szolcsányi, Janós, Kata Bölcskei, Árpád Szabó, et al.. (2004). Analgesic effect of TT-232, a heptapeptide somatostatin analogue, in acute pain models of the rat and the mouse and in streptozotocin-induced diabetic mechanical allodynia. European Journal of Pharmacology. 498(1-3). 103–109. 42 indexed citations
19.
Hegedűs, Tamás, et al.. (2002). Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 1587(2-3). 318–325. 173 indexed citations
20.
Páska, Csilla, László Őrfi, István Kövesdi, et al.. (1999). [Biological activity and structure of antitumor compounds from Plantago media L].. PubMed. 69(5). 232–9. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ching‐Shih Chen Breakdown of academic impact, for papers by Pramod S. Pandey Breakdown of academic impact, for papers by Stig Linder Breakdown of academic impact, for papers by Ross L. Stein Breakdown of academic impact, for papers by Alex N. Bullock Breakdown of academic impact, for papers by Ji Cao Breakdown of academic impact, for papers by John F. Timms Breakdown of academic impact, for papers by Juan Carlos Lacal Breakdown of academic impact, for papers by Mikihiko Naito Breakdown of academic impact, for papers by Klaus P. Hoeflich
Rankless by CCL
2026